The liver is an important target organ for gene transfer due to its large capacity for synthesizing serum proteins and its involvement in numerous genetic and acquired diseases. Previously, we and others have shown that an efficient gene transfer to liver cells in vivo can be achieved by an intravenous injection of plasmid DNA using a hydrodynamics-based procedure. In this study, we systematically characterized the expression of transgene encoding a secretory protein in mouse. Using human ␣1-antitrypsin (hAAT) gene as a reporter, we demonstrate that the serum level of hAAT can reach as high as 0.5 mg/ml by a simple
Introduction
Methods for introduction of genes into tissues such as liver have been actively sought in the past. Liver is an important target organ for gene delivery due to its function in synthesizing many serum proteins and its involvement in numerous genetic and acquired diseases. A variety of vectors have been used for introducing genes into the liver, including recombinant retrovirus, [1] [2] [3] [4] [5] adenovirus, 6 -10 adeno-associated virus, [11] [12] [13] and nonviral vectors such as cationic polymers, [14] [15] [16] liposomes, 17, 18 and reconstituted chylomicron remnants. 19 Although significant progress has been made in demonstrating successful gene delivery to the liver, a number of remaining difficulties and technical problems are associated with each of these methods. While retroviral vectors can generate a long-term expression of the introduced gene in the liver by using either ex vivo or direct injection, the procedure normally requires partial hepatectomy 20 or liver damage 2 in order to stimulate cell division. Adenoviral vectors allow for an efficient gene transfer to the liver, but gene expression normally lasts for a short time period due to host immune response against viral proteins. [21] [22] [23] Adenoassociated viral vectors, although they produce a longterm gene expression, suffer from their inability to deliver genes with a size of more than 5.2 kb. 24 The major tail vein injection of 10-50 g plasmid DNA into a mouse. The serum hAAT reaches the peak level 1 day after DNA injection and then declines during the following 2 to 4 weeks to 2-5 g/ml, a level which persists for at least 6 months. Southern analysis of extracted DNA and RT-PCR analysis of RNA from the liver reveal that hAAT gene is active and present as episomal form after 6 months. These results suggest that the hydrodynamics-based transfection procedure provides a valuable tool for screening genes for therapeutic purposes in whole animals. Gene Therapy (2000) 7, 1344-1349.
limitation of current nonviral vectors is low transfection efficiency.
To overcome these problems, we 25 and Zhang et al 26 have explored the possibility of transfecting the liver cells by a rapid injection of large volume of plasmid DNA solution, the so-called 'hydrodynamics-based procedure'. 25 Using this method, we demonstrated that up to 45 g of luciferase protein per gram of liver can be obtained by a single tail vein injection of as little as 5 g of pCMV-Luc plasmid DNA. In this article, we report the results from a series of experiments designed to characterize the pattern of transgene expression using human ␣1-antitrypsin (hAAT) gene as a reporter, which encodes a secretory protein with a molecular weight of 51 kDa. 27 The goal of this study is to identify the factors that affect hAAT gene expression in mice transfected by the hydrodynamicsbased procedure.
Results

DNA dose-dependent hAAT gene expression
We first established the relationship between the serum hAAT level and the amount of pCMV-hAAT plasmid DNA each animal received. In these experiments, mice were intravenously injected, via the tail vein, with pCMV-hAAT plasmid DNA at a dose of 0.05, 0.5, 5, 10, 25 and 50 g per mouse, respectively. Serum samples were prepared from animals 24 h after DNA infusion and analyzed by Western blot. Data in Figure 1 show that hAAT protein is readily detected in animals at the dose of 0.5 g DNA or greater. The increased intensity of the hAAT protein band (lanes 2-4) suggests that the serum concentration of hAAT correlates with the amount of DNA each animal received. Under our experimental conditions, the level of serum hAAT reached saturation at a DNA dose of approximately 5 g per mouse.
Site of transgene expression
To identify the site of transgene expression, we examined the level of transgene expression in different organs using ␤-galactosidase (LacZ) gene as the reporter. Eight hours following infusion of 10 g of pCMV-LacZ plasmid DNA, animals were killed and LacZ gene expression was assessed in organs including the lung, heart, spleen, liver and kidney. It is evident in Figure 2 that liver is the only organ that expressed LacZ gene at a detectable level under our experimental conditions. The LacZ gene expression in the liver (Figure 2a ) seems restricted to certain areas as X-gal-positive cells are clustered around the hepatic vein.
Persistence of hAAT gene expression
The method of quantitative ELISA was employed to evaluate persistence of hAAT gene expression. In these experiments, each mouse was injected on day 0 with 10, 25 or 50 g of pCMV-hAAT plasmid DNA which are above the saturation amount of 5 g per mouse resulting from Western blot analysis (Figure 1 ). Blood samples were collected at appropriate times and the serum concentration of hAAT protein was determined. Data presented in Figure 3 show that the serum hAAT reached the peak level of 200-500 g/ml 1 day after injection in animals injected with 10-50 g of pCMV-hAAT plasmid DNA. The decrease of the hAAT protein level was biphasic. The hAAT level dropped approximately 100-fold from day 1 to day 30 and persisted at a lower level for up to 6 months. The serum hAAT concentration 6 months after transfection was approximately 2-5 g/ml in animals each injected with 10-50 g of pCMV-hAAT plasmid DNA.
To confirm that hAAT genes were still transcriptionally active in the liver 6 months after transfection, total RNA Gene Therapy was extracted from mouse liver and a RT-PCR was performed using primers spanning the 560 bp region of hAAT gene. A DNA fragment with the predicted size was obtained in all transfected animals (Figure 4a ), suggesting that hAAT gene in mouse liver remained active in transcription.
To evaluate the status of pCMV-hAAT plasmid DNA in liver cells 6 month after DNA injection, total DNA was prepared from the liver samples, digested with ClaI, and subjected to Southern analysis using hAAT gene as a probe. Data in Figure 4b show that hAAT gene remains episomal as suggested by its identical size to that of control plasmid DNA (lane 1). A strong band corresponding to the size of linearized pCMV-hAAT plasmid was seen in all transfected animals. Different intensities of detected DNA bands were seen in both RT-PCR and Southern analysis, indicating the existence of animal-to-animal variation.
Persistence of pCMV-hAAT plasmid DNA in the liver To elucidate the mechanisms underlying the biphasic change in serum concentration of hAAT protein after DNA administration, we examined, using Southern analysis, the level of hAAT gene in the liver as a function of time. It is evident from the results shown in Figure 5 that hAAT gene was present in all liver samples, although more hAAT gene was detected within 24 h post-DNA injection. These data suggest that some pCMV-hAAT plasmid DNA introduced into liver cells appear to be degraded within 1 day and those that survived remained stable for at least 6 months.
Effect of repeated administration
The effect of repeated injection of pCMV-hAAT plasmid DNA on the serum concentration of hAAT protein was evaluated in mice injected with different amounts of pCMV-hAAT plasmid DNA. In these experiments, animals were each injected on day 0 with 0.05, 0.5 or 10 g of pCMV-hAAT plasmid DNA. The repeated administration of the same type and amount of plasmid DNA was performed on days 30 (second injection) and 60 (third injection). The serum hAAT was examined on days 1, 3, 5, 10, 20 and 30 after each DNA administration. Data in Figure 6 show that animals responded to each of the three injections in an identical dose-dependent manner. The serum hAAT peaked at day 1 after each DNA administration with the highest level in animals injected with 10 g of pCMV-hAAT plasmid DNA, followed by that of animals receiving 0.5 g and 0.05 g of the same plasmid DNA.
Discussion
The liver is an important target organ for gene transfer due to its function in synthesizing many serum proteins and its involvement in numerous genetic and acquired diseases. In this and previous studies, 25, 26 we demonstrated that successful transfer and expression of transgene in the liver can be achieved by systemic administration of plasmid DNA using a hydrodynamics-based procedure. Such success probably results from a reflux of DNA solution into the liver via the hepatic vein due to a transient cardiac congestion. Kinetic analysis of transgene expression revealed that the level of transgene product reaches maximal level 1 day after transfection, declines thereafter for approximately 1 month and then persists at a lower level for more than 6 months. The pattern of hAAT gene expression is similar to that of human growth factor gene 28 and luciferase gene (Liu D, unpublished data) in mice.
One important piece of information obtained in this study is the long-term gene expression. With the exception of intramuscular injection of plasmid DNA, 29 it has been postulated that naked DNA, once entering the target cells either by nonviral vector-mediated procedure or other physical methods, is quickly degraded, The kinetic pattern of hAAT in serum shown in Figure  3 probably results from an equilibrium between the rate of hAAT elimination and the rate of production by the transfected liver cells. Considering that the blood halflife of hAAT in mouse is about 15 h, 33 which has been confirmed by our own measurements, it is likely that hAAT production dominates the serum level at an early time-point when the amount of hAAT gene in the liver is maximal. However, such a production rate cannot be maintained as the liver cells start to lose some of the DNA introduced. Once hAAT production by the liver cells falls below the rate of hAAT elimination from the blood, hAAT serum concentration decreases. Interestingly, as shown in Figure 5 , while a significant decrease of the amount of hAAT gene in the liver occurs between 1 and 3 days, a significant level of hAAT DNA was detected in the liver for as long as 6 months. Results from RT-PCR analysis of liver samples (Figure 4a ) demonstrate that these remaining hAAT gene molecules in the liver are still active and responsible for maintaining a relatively constant level of hAAT in the blood. It is unclear at the present time how some of the plasmid DNA injected remained active for such a long time.
Data presented in Figure 6 suggest that the level of transgene expression can be manipulated by controlling the amount and frequency of plasmid DNA administration. For example, injection of 10 g of plasmid DNA into animals results in a serum concentration of hAAT at 200 g/ml, compared with 10 g/ml and 1 g/ml in animals injected with 0.5 and 0.05 g of plasmid DNA, respectively. After a relatively fast decline, the level of serum hAAT becomes unchanged for an extended period of time at levels that are directly proportional to the amount of pCMV-hAAT plasmid DNA injected. Regardless of the plasmid dose, these patterns of expression kinetics are almost identical after repeated injections. From a pharmaceutical point of view, the pattern seen in Figure  6 represents a typical profile of drug concentration in animals after administration, suggesting that the level of transgene expression in animals using our method can be achieved in a predictable manner. Such controllability over the level of transgene expression is extremely important in cases where the level of gene product is critical and needs to be tightly regulated.
In summary, data provided in this and our previous report 25 clearly show that high level transgene expression can be achieved by a simple tail vein injection of plasmid DNA using a hydrodynamics-based procedure. This simple transfection procedure may prove to be a valuable alternative to viral and nonviral vectors for in vivo transfection of the liver in animals. With this technique, it is now possible to screen many different genes and/or their combinations for their therapeutic activity in animal models, without involving any sophisticated procedures that are essential for the preparation of most commonly used viral and nonviral vectors.
Gene Therapy
Materials and methods
Materials
Goat anti-hAAT antibody was purchased from Incstar Corporation (Stillwater, MN, USA). Donkey anti-goat IgG antibody conjugated with horseradish peroxidase was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ECL kit and biotinylation reagents were from Amersham Life Science (Piscataway, NJ, USA). Rabbit anti-hAAT antibody, streptavidin-horseradish peroxidase conjugate and purified hAAT were from Sigma (St Louis, MO, USA). X-gal was from Life Technology (Rockville, MD, USA). Trizol reagent and PCR Supermix solution were from Gibco BRL (Grand Island, NY, USA). RNA PCR kit was from Perkin Elmer (Branchburg, NJ, USA). CD-1 mice (male, 18-20 g) were purchased from Charles River Laboratory (Wilmington, MA, USA). Five animals, otherwise indicated, were used for each data point.
Plasmid pCMV-hAAT plasmid (6.1 kbp) with one ClaI site was provided by Dr Xiang Gao (Center for Lung Research, Vanderbilt University) in which hAAT gene was cloned into the backbone of pCMV4 (Invitrogen, Carlsbad, CA, USA). pCMV-LacZ plasmid was constructed by cloning the bacterial ␤-galactosidase (LacZ) gene into the backbone of pcDNA3 (Invitrogen, Carlsbad, CA, USA). The expression of both reporter genes is driven by human cytomegalovirus immediate-early promoter (CMV). Plasmid DNA was purified by the CsCl-density gradient centrifugation method 34 and kept in saline at −20°C until use. Purity of plasmid DNA was checked by absorbency at 260 and 280 nm and by 1% agarose gel electrophoresis.
In vivo transfection
Animals were injected via the tail vein with plasmid DNA in 1.6 ml saline using a 3-cc latex-free syringe with a 27.G needle (Becton Dickinson, Franklin Lakes, NJ, USA). The injection rate was kept at 0.3 ml/s or greater.
Western analysis
Mouse sera were collected from mice 24 h after injection of pCMV-hAAT plasmid. Proteins were separated on 10% SDS-PAGE and transferred to a PDVF membrane using a semi-dry blot device (BioRad, Hercules, CA, USA). The membrane was blocked overnight at 4°C with 5% bovine serum albumin (BSA) in PBS-Tween buffer (0.2% Tween 20 in PBS) and then incubated with a goat anti-hAAT antibody (1:2000 dilution in 1% BSA in PBSTween buffer) for 1 h at room temperature. After washing with 1% BSA in PBS-Tween buffer, membrane was incubated with donkey anti-goat antibody conjugated with horseradish peroxidase (1:10 000 dilution in 1% BSA in PBS-Tween buffer). Protein band for hAAT was visualized using an enhanced chemiluminescence (ECL) method.
Determination of serum concentration of hAAT by ELISA Serum samples were collected at appropriate times and diluted serially with 1% BSA in PBS-Tween buffer before a standard ELISA was performed. A rabbit anti-hAAT polyclonal antibody (12.6 g/ml in carbonate buffer, pH 8.8) was used for coating the ELISA plate (room temperature, overnight). The coated wells were blocked with 4% BSA in PBS-Tween buffer. After incubation with diluted serum sample, the biotinylated goat anti-hAAT polyclonal antibody (1:1000 dilution in 1% BSA in PBSTween buffer) was added and incubated for 1 h at room temperature. After washing, streptavidin-horseradish peroxidase conjugate (1:50000 dilution 1% BSA in PBSTween buffer) was then added to each well and incubated for 1 h. With the exceptions of blocking buffer (200 l per well) and washing buffer (400 l per well), the sample volume used was 100 l per well. The absorbency at 450 nm for each well was obtained after addition of peroxidase substrate (3,3Ј,5,5Ј-tetramethylbenzidine) using an ELISA reader. The hAAT concentration was calculated based on the standard curve established using pure hAAT. To minimize the plate-to-plate variation, the standard curve was established in each of the 96-well plates used. The concentration range for the standard curve was 0 to 32 ng/ml. The hAAT standard was prepared by dissolving the lyophilized powder of hAAT in normal mouse serum at 500 g/ml.
X-gal staining
The level of LacZ gene expression in the internal organs including the lung, heart, liver, spleen and kidney was determined by X-gal staining method. 35 Tissue sections (10 m thickness) were made 8 h after plasmid injection and stained with X-gal solution for 2 h. Hematoxylineosin (H-E) staining was used for histological analysis.
RT-PCR analysis of hAAT gene expression in mouse liver 6 months after transfection Total RNA was extracted from approximately 200 mg of mouse liver using Trizol reagent according to the manufacturer's instructions. Single-stranded cDNA was then prepared from 1.5 g of extracted RNA using a Perkin Elmer RNA PCR kit according to the protocol provided by the manufacturer. Two l of the sample were amplified in a 40 l PCR reaction using PCR Supermix solution (Gibco BRL, Grand Island, NY, USA) and primers spanning the 560 bp region of hAAT gene 5Ј-CTGGGACAGTGAATCGACAATGC-3Ј and 5Ј-TCTGT TTCTTGGCCTCTTCGGTG-3Ј). PCR conditions were 94°C for 1 min, 65°C for 1 min and 72°C for 1 min for 30 cycles. Fifteen l of sample were analyzed by 1.5% agarose gel electrophoresis. Control RT-PCR reaction was performed with liver sample from a normal mouse.
Southern analysis
Total DNA was extracted from the homogenized liver using a published procedure. 30 The livers were collected and immediately frozen on dry ice. Approximately 200 mg of liver sample were used for DNA extraction. Twenty-five g of total DNA from each sample were digested overnight at 37°C using 30 units of ClaI and then separated on 1% agarose gel. DNA bands were transferred overnight on to a GeneScreen Plus membrane. After prehybridization with sonicated salmon sperm DNA in prehybridization buffer (50% deionized formamide, 250 mm sodium phosphate, 250 mm NaCl, 1 mm EDTA, 100 g/ml sonicated salmon sperm DNA), the membrane was incubated at 42°C for 16-20 h with 32 Plabeled probe. The 32 P-labeled probe was prepared using full hAAT gene sequence cut from pCMV-hAAT plasmid DNA and a random primed DNA labeling kit (DuPont NEN, Boston, MA, USA). The hybridized bands were visualized by autoradiography.
